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Background: Irisin is an adipomyokine with claimed anti-obesity and anti-diabetic effects.
This  hormone has been insufﬁciently studied in patients with advanced chronic kidney
disease (CKD).
Objective: To perform an exploratory analysis of serum irisin levels in patients undergoing
different CKD treatments.
Method: Following a cross-sectional design, we estimated serum levels of irisin in 95 patients
with CKD managed conservatively (advanced CKD), with peritoneal dialysis (PD) or with
haemodialysis, and compared our ﬁndings with a control group of 40 healthy individuals.
We  investigated the correlations between serum irisin and demographic, clinical, body com-
position and metabolic variables.
Results: Irisin levels were lower in all the CKD groups than in the control group. The uni-
variate analysis revealed limited correlations between irisin, on the one hand, and fat (but
not  lean) mass, glomerular ﬁltration rate (GFR) and plasma albumin and bicarbonate, on
the  other. The multivariate analysis conﬁrmed that advanced CKD patients managed con-
servatively (difference 111.1 ng/mL), with PD (25.9 ng/mL) or haemodialysis (61.4 ng/mL) (all
p  < .0005) presented lower irisin levels than the control group. Furthermore, PD patients pre-
sented higher serum levels of irisin than those on haemodialysis (difference 39.4 ng/mL,p  = .002) or those managed conservatively (24.4 ng/mL, p = .036). The multivariate analy-sis  also identiﬁed plasma bicarbonate (B = 3.90 per mM/l, p = .001) and GFR (B = 1.89 per
mL/min, p = .003) as independent predictors of irisin levels. Conversely, no adjusted cor-
relation between irisin and body composition markers was found.
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Conclusions: Serum irisin levels are low in patients with CKD and show a consistent corre-
lation  with GFR and plasma bicarbonate levels. PD patients present higher levels of irisin
than those managed conservatively or with haemodialysis. Our study conﬁrms a general
inconsistency of the association between serum irisin levels, on the one hand, and body
composition and metabolic markers, on the other.
© 2016 Sociedad Espan˜ola de Nefrologı´a. Published by Elsevier Espan˜a, S.L.U. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
Niveles  séricos  de  la  adipomioquina  irisina  en  pacientes  con  enfermedad
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Antecedentes: La irisina es una adipomioquina con posibles efectos antiobesidad y antidia-
béticos. Esta hormona ha sido insuﬁcientemente estudiada en pacientes con enfermedad
renal  crónica (ERC) avanzada.
Objetivo: Realizar un análisis exploratorio de los niveles séricos de irisina en pacientes con
diferentes modalidades de tratamiento de la ERC.
Método: Según disen˜o transversal, estimamos niveles de irisina en 95 pacientes con ERC
manejados conservadoramente (ERCA), con diálisis peritoneal (DP) o con hemodiálisis,
comparándolos con un grupo control de 40 individuos sanos. También investigamos las
correlaciones entre irisina sérica y variables demográﬁcas, clínicas, metabólicas y de com-
posición corporal.
Resultados: Los niveles de irisina fueron más bajos en cualquier grupo de pacientes que en
los  controles. El análisis univariante desveló correlaciones moderadas entre irisina, por un
lado, y masa grasa (pero no magra), ﬁltrado glomerular (GFR) y albúmina y bicarbonato plas-
mático, por otro. El análisis multivariante conﬁrmó que los pacientes con ERCA (diferencia
111,1  ng/mL), en DP (25,9 ng/mL) o hemodiálisis (61,4 ng/mL) (todos p < 0,0005) presentaban
niveles ajustados más bajos de irisina que los controles. Asimismo, los pacientes en DP pre-
sentaban niveles más altos de la hormona que los de hemodiálisis (diferencia 39,4 ng/mL;
p  = 0,002) o ERCA (24,4 ng/mL; p = 0,036). El análisis multivariante también identiﬁcó bicar-
bonato plasmático (B = 3,90 por mM/L; p = 0,001) y GFR (B = 1,89 por mL/min; p = 0,003) como
predictores independientes de los niveles de irisina. Por el contrario, no observamos cor-
relación ajustada entre irisina y marcadores de composición corporal.
Conclusiones: Los niveles de irisina son bajos en pacientes con ERC, y muestran correlación
consistente con GFR y bicarbonato plasmático. Los pacientes en DP presentan niveles más
altos  de irisina que los manejados conservadoramente o con hemodiálisis. Nuestro estudio
conﬁrma una inconsistencia general en los análisis de asociación entre irisina sérica, por
un  lado, y marcadores metabólicos y de composición corporal, por otro.
© 2016 Sociedad Espan˜ola de Nefrologı´a. Publicado por Elsevier Espan˜a, S.L.U. Este es un
artı´culo Open Access bajo la licencia CC BY-NC-ND (http://creativecommons.org/licenses/
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n recent years, muscle tissue has been emerging as an
mportant endocrine organ, involved in regulating many  phys-
ological processes.1–3 Irisin4 is an adipomyokine that appears
o participate in regulating energy metabolism and other
hysiological processes. Its best-known and probably most
mportant function is to break down body fat, thereby con-
erting it into brown adipose tissue.4 The main consequence
s an increase in energy expenditure, caused by the thermo-
enic nature of brown fat. This phenomenon contributes to
he regulation of body temperature as an immediate effect but
ther potential consequences include weight loss and there-
ore a decrease in plasma levels as well as an improvementby-nc-nd/4.0/).
in insulin tolerance. Therefore, irisin could have a beneﬁcial
effect against obesity and as an antidiabetic agent.5,6
The effects of chronic kidney disease (CKD) on the synthe-
sis and secretion of irisin, and its inﬂuence on the complex
metabolic disorders of CKD patients, have not been investi-
gated sufﬁciently. Some studies have reported relatively low
levels of serum irisin in patients with advanced CKD,7–9 but
the comparative effect of different treatment methods has
not been evaluated adequately. In addition, the correlations
observed between irisin and different clinical, biochemical
and metabolic markers in these patients are controversial.
We have undertaken a cross-sectional, exploratory analysis
of a large sample of patients with CKD on different modalities
of treatments. Our goal was to conduct a comparative anal-
ysis of irisin levels and uncover potential associations with
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different demographic, clinical, biochemical, metabolic and
body composition markers.
Population  and  method
Following a cross-sectional design, we investigated serum
irisin levels in a sample taken consecutively from a set of
advanced CKD patients managed conservatively (ACKD), with
peritoneal dialysis (PD) or with haemodialysis (HD) at our cen-
tre. We  used the following inclusion/exclusion criteria:
1. Aged between 18 and 80.
2. CKD, with estimated glomerular ﬁltration rate (GFR)
<30 mL/min.
3. No signiﬁcant clinical events for at least 3 months prior to
inclusion.
4. Full capacity to understand the objectives and conditions
of the study.
5. Written informed consent.
The primary study variable was serum irisin. We investi-
gated the correlation of this variable with the following:
(a) Demographic data: age, gender, diabetes, comorbid-
ity (Charlson Comorbidity Index), treatment method
(ACKD, PD, HD), duration of dialysis, blood pressure
(at the time of sampling) and treatment with statins,
renin–angiotensin–aldosterone system (RAAS) antago-
nists and erythropoiesis-stimulating factors (ESAs).
(b) Body composition: body weight, body mass index
(weight/height2), total body water, intra-/extracellular
water ratio, overhydration, and body fat and lean body
mass (corrected for body surface area [BSA]). The last
5 parameters were estimated using a multifrequency
bioimpedance analysis (BIA) device (BCM, Fresenius, Hei-
delberg, Germany).
(c) Laboratory: GFR (mean renal urea and creatinine clear-
ances), proteinuria, haemoglobin, albumin, cholesterol,
triglycerides, uric acid, bicarbonate, calcium, phosphate
(automated analyser), parathyroid hormone (PTH) (IRMA,
Nichols Inst., San Juan Capistrano, USA), interleukin 6
(ELISA, Abcam, Cambridge, UK) and C-reactive protein
(CRP) (Immunoturbidimetry, Roche, Mannheim, Germany).
d) Hormonal: blood glucose, C-peptide (Chemiluminescence,
Immulite 2000, Siemens, Munich, Germany), insulin
(RIA, CIS Bio Int. Cedex, France), HOMA calculator
(by Matthews),10 growth hormone (RIA, Nichols), IGF1
(Immunoassay, Nichols), leptin (ELISA, R&D Systems,
Minneapolis, USA) and 25-OH vitamin D test (Chemi-
luminescence, Centaur, Siemens, Erlangen, Germany).
(e) To select the method for estimating irisin levels, we con-
ducted a preliminary analysis of the correlation between
2 commercially available ELISA kits (EK-067-29 by Phoenix
Pharmaceuticals, Burlingame, USA And AG-45A-0046 by
Adipogen International, San Diego, USA). On average, the
EK-067-29 kit provided values 41% higher than the AG-45A-
0046 kit. The AG-45A-0046 kit was selected for the greater
internal consistency of the estimates, which were made in
duplicate. Blood samples were placed in serum separator;3 6(5):496–502
tubes and centrifuged at 3000 × g for 15 min  at 4 ◦C. The
serum was stored at −80 ◦C until analysis.
The variables are presented as means (± standard deviation
[SD]) except for abnormal distributions (median with ampli-
tude). Univariate comparisons were generated by ANOVA and
Kruskal–Wallis and distribution tests 2. Univariate corre-
lations were estimated using Spearman’s rank correlation
coefﬁcient. The adjusted correlations between serum irisin
and different variables were investigated using multiple
regression models (stepwise). We  used a random sample of 40
healthy individuals, adjusted for age, gender and body mass
index as a reference control group. We used SPSS 19.0 software
for data management.
Results
The number of patients asked to take part in the study was
105 patients. Seven patients refused to participate and 3
were excluded for having developed clinical events during the
screening phase. Thus, the study group was composed of 95
patients. The main demographic and body composition vari-
ables are shown in Table 1, while the biochemical variables and
those concerning treatments are shown in Table 2. Patients
on HD had a longer average time on dialysis than those on
PD, as well as lower values for body weight and body fat, and
a higher mean level of overhydration than the other 2 study
groups (Table 1). The differences observed for GFR values were
as anticipated (Table 2). The healthy control group consisted
of 20 men  and 20 women, aged 56.6 ± 8.7 and with a body mass
index of 27.6 ± 4.6 kg/m2.
Table 3 shows the main hormonal variables analysed.
Serum irisin levels were lower in any of the groups of
patients than in the healthy controls. In addition, compar-
isons between the groups of patients revealed lower levels of
adipomyokine in patients on HD than in those treated with PD
(Fig. 1). Among patients, irisin levels were similar in diabet-
ics (108.0 ± 32.4 ng/mL) and non-diabetics (113.3 ± 45.4 ng/mL)
(p = 0.77). Table 4 shows the main univariate correlations for
irisin. A moderate direct association with body fat (BIA),
diastolic blood pressure and GFR was observed. The most
signiﬁcant association was observed between serum con-
centration of irisin and bicarbonate, which was relatively
consistent for the different groups, but it did not reach statisti-
cal signiﬁcance in PD patients. Conversely, irisin levels showed
no association with treatment with statins, RAAS antagonists
or ESAs. Nor did we observe consistent associations between
irisin levels and the serum concentration of the hormones
measured (Table 4).
The multivariate analysis conﬁrmed that, after adjusting
for age, gender and body fat, irisin levels were lower in
patients with CKD (mean difference: 111.1 ng/mL, 95% CI:
83.0/139.2; p < 0.0005) and patients treated with PD (25.9 ng/mL;
95% CI: 15.1/36.7; p < 0.0005) or HD (61.4 ng/mL; 95% CI:
45.2/77.6; p < 0.0005) than in healthy controls. When consid-
ering patients only, the multivariate analysis showed plasma
bicarbonate, GFR and modality of treatment were the only con-
sistent predictors of serum irisin (Table 5). In addition, patients
on PD had higher levels of irisin than patients with CKD or
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Table 1 – Demographic variables and body composition.
ACKD Peritoneal dialysis HD p
N 30 35 30
Age (years) 57.0 (12.4) 60.8 (12.3) 56.1 (13.3) 0.29
Gender (% male) 60.0 61.1 50.0  0.62
Diabetes (%) 10 (33.3) 16 (44.4) 12 (40) 0.87
Charlson Comorbidity Index 4.5 (1.8) 5.3 (2.0) 5.4 (1.9) 0.11
Body weight (kg) 78.1 (12.5) 75.5 (11.5) 64.7 (13.7) 0.0005a
Body mass index (kg/m2) 28.6 (4.3) 28.2 (3.9) 24.6 (3.7) 0.001a
Systolic BP (mmHg) 142.9 (18.1) 144.1 (19.3) 141.9 (23.5) 0.91
Diastolic BP (mmHg) 82.6 (11.4) 83.0 (13.0) 79.1 (13.5) 0.16
Time on dialysis (months) N/A 29.8 (29.2) 60.7 (52.3) 0.0005a
Total body water (L) (BIA) 34.8 (6.2) 34.3 (6.9) 31.3 (7.4) 0.10
Intra-/extracellular water (BIA) 0.92 (0.11) 0.97 (0.14) 0.98 (0.13) 0.12
Body fat (kg)b (BIA) 15.4 (5.4) 15.0 (4.7) 11.5 (85.4) 0.008a
Lean body mass (kg)b (BIA) 13.6 (5.9) 12.5 (2.7) 11.7 (3.2) 0.20
Overhydration (L) (BIA) 0.70 (1.15) 1.40 (1.72) 1.83 (2.37) 0.059
BIA: multifrequency bioimpedance; ACKD: advanced chronic kidney disease (estimated GFR < 30 mL/min); HD: haemodialysis; N/A: not appli-
cable; BP: blood pressure.
Comparisons using ANOVA and analysis 2.
a Signiﬁcant difference between HD and the other 2 groups (Scheffé’s method).
b Corrected for body surface area.
Table 2 – Laboratory and treatment variables.
ACKD Peritoneal dialysis HD p
N 30 35 30
GFR (mL/m) 18.4 (8.3)a 5.8 (4.3) 0.9 (1.3) 0.0005
Proteinuria (g/24 h) 1.8 (1.8)a 1.1 (1.4) 0.2 (0.4) 0.0005
Haemoglobin (g/dL) 11.3 (1.7) 11.6 (1.4) 11.5 (1.6) 0.77
ESFs (%) 8 (26.7)a 22 (61.1) 27 (90.0) 0.0005
Albumin, plasma (g/dL) 4.0 (0.4)a 3.7 (0.4) 3.7 (0.7) 0.007
Cholesterol, plasma (mg/dL) 161.6 (40.2) 155.9 (44.4) 139.1 (28.5)a 0.0005
HDL cholesterol (mg/dL) 42.3 (10.9) 41.1 (14.7) 43.3 (11.1) 0.50
LDL cholesterol (mg/dL) 90.9 (38.9) 93.8 (39.8) 88.8 (35.5) 0.79
Triglycerides, plasma (mg/dL) 146 (60.445)a 106 (49.233) 108 (33.242) 0.020
Uric acid, plasma (mg/dL) 7.6 (1.5)a 5.9 (1.1) 6.2 (1.2) 0.0005
Bicarbonate, plasma (mM/L) 23.2 (4.6) 28.1 (3.5)a 24.5 (2.6) 0.0005
Calcium, plasma (mg/dL) 9.3 (0.5) 9.0 (0.6) 9.1 (0.8) 0.42
Phosphate, plasma (mg/dL) 4.8 (1.1) 4.8 (0.9) 4.9 (1.2) 0.94
PTH, plasma (pg/mL) 306.8 (194.6) 309.8 (220.8) 438.0 (370.4) 0.10
Interleukin 6, plasma (pg/mL) 1.1 (0.5; 31.0) 2.8 (0.5; 35.0) 3.0 (1.0; 66.0) 0.29
CRP, plasma (mg/dL) 0.33 (0.10; 11.30) 0.45 (0.11; 6.40) 0.50 (0.10; 12.40) 0.15
RAAS antagonists (%) 15 (50.0) 15 (41.7) 8 (26.7) 0.17
Statins (%) 25 (83.3) 26 (72.2) 19 (63.3) 0.22
Values indicate means (SD) except triglycerides, CRP and interleukin 1, expressed as a median (range), ANOVA.
ACKD: advanced chronic kidney disease; ESFs: erythropoiesis-stimulating factors; GFR: glomerular ﬁltration rate; HD: haemodialysis; HDL: high-
density lipoprotein; LDL: low-density lipoprotein; CRP: C-reactive protein; PTH: parathyroid hormone; RAAS: renin–angiotensin–aldosterone
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a Signiﬁcant difference compared with the other 2 groups (Scheffé’s 
hose treated with HD. These differences persisted after adjus-
ing for body fat and lean body mass (BIA).
iscussion
risin is a degradation peptide made of 112 amino acids,
esulting from ﬁbronectin type III domain-containing protein 5
hen broken down  by proteases.4 It was initially categorised
s a myokine, as it was considered to be essentially synthe-
ised in skeletal and cardiac muscle. But more  recent workod).
indicates that fat11,12 and, to varying degrees, other peripheral
tissues5 are also able to secrete this factor. Irisin maintains
a remarkable molecular homology across different species of
mammals.13
The mechanisms that regulate the synthesis and subse-
quent secretion of irisin have not been fully elucidated. The
initial belief that exercise and physical conditioning stimu-
late the synthesis and secretion of irisin has been conﬁrmed
by most, though not all subsequent investigations.5 Both cold
and heat also appear to stimulate the release of this factor.
Moreover, it has been noted that levels of irisin are higher
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Table 3 – Hormonal variables.
ACKD Peritoneal dialysis HD Healthy controls p
Blood glucose (mg/dL) 98.4 (37.8) 114.0 (37.1) 101.3 (37.3) 95.5 (13.4) 0.11
C-peptide, plasma (ng/mL) 4.6 (3.7)a 9.5 (6.7) 9.0 (5.1) – 0.001
Insulin, plasma (mcIU/mL) 20.5 (19.8) 21.1 (17.7) 13.4 (6.6) 7.1 (5.0)e 0.0005
HOMA index 3.65 (2.30) 5.21 (2.51)b 3.46 (2.50) 1.67 (1.40)f 0.011
GH, plasma (ng/mL) 0.52 (0.02; 13.80) 0.83 (0.11; 13.54) 2.25 (0.28; 23.71)c 0.47 (0.05; 9.00)g 0.0005
IGF1, plasma (mg/dL) 209.6 (93.2) 260.6 (129.5) 199.3 (89.7) 139.0 (67.1)e 0.0005
Leptin, plasma (pg/mL) 141.2 (105.3) 161.1 (106.1) 74.9 (80.0)c 26.6 (12.7)f 0.004
25-OH vit. D, plasma (ng/mL) 19.2 (12.8) 17.8 (10.4) 11.5 (6.2)c – 0.010
Irisin, serum (ng/mL) 109.1 (34.3) 132.2 (45.3) 95.1 (41.2)d 215.6 (53.1)f 0.0005
ACKD: advanced chronic kidney disease; HD: haemodialysis; IGF1: insulin-like growth factor.
The values indicate the means (SD) except GH (growth hormone), expressed as a median (range), ANOVA.
a p = 0.01 vs. PD and HD.
b p < 0.05 PD vs. ACKD and HD.
c p < 0.05 HD vs. ACKD and PD.
d p = 0.006 PD vs. HD (Scheffé’s method), other differences amongst patients NS.
e p < 0.01 vs. ACKD and PD.
f p < 0.001 vs. patients (any group).
g p = 0.003 vs. HD.
in men  than in women, and are elevated in obese patients,
with a direct correlation with body fat and body mass index,6
although these associations have not been conﬁrmed by other
studies.5 It has been hypothesised that elevated levels of
irisin in obese patients would be a compensatory mechanism
for the progressive accumulation of body fat6 and also that
irisin could play a role in improving carbohydrate metabolism
observed after weight loss in obese patients with metabolic
syndrome.14 Finally, some studies have reported relatively low
levels of irisin in type 2 diabetics15,16 and patients with fatty
liver disease.6
Table 4 – Univariate correlations between serum irisin and mai
All ACK
Age 0.09 (0.42) 0.35 (0
Gender 0.15 (0.18) 0.13 (0
Charlson Comorbidity Index 0.025 (0.83) 0.36 (0
Body mass index 0.14 (0.21) 0.09 (0
Lean body mass by BSA (BIA) −0.12 (0.29) 0.001 (0
Body fat by BSA (BIA) 0.21 (0.07) 0.10 (0
GFR 0.21 (0.07) 0.40 (0
Proteinuria 0.00 (0.99) −0.04 (0
Albumin (plasma) −0.25 (0.030) −0.15 (0
Bicarbonate (plasma) 0.44 (0.0005) 0.46 (0
C-reactive protein (plasma) −0.15 (0.20) −0.15 (0
Interleukin 6 (plasma) −0.16 (0.20) −0.18 (0
Blood glucose 0.01 (0.94) −0.03 (0
Insulin (plasma) 0.10 (0.39) −0.39 (0
HOMA index −0.24 (0.20) −0.37 (0
C-peptide (plasma) −0.05 (0.67) −0.38 (0
GH (plasma) −0.12 (0.28) −0.06 (0
IGF1 (plasma) −0.04 (0.73) −0.47 (0
Leptin (plasma) 0.18 (0.23) 0.14 (0
BIA: bioimpedance; GFR: glomerular ﬁltration rate; GH: growth hormone; I
The values indicate Spearman’s rank correlation coefﬁcients (p). Other va
acid, cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, haemog
values.
Statistically signiﬁcant correlations are in bold.The effect of renal disease on serum irisin levels
has not been adequately investigated. Irisin levels could
maintain an inverse correlation with grade of proteinuria in
type 2 diabetes.17 Wen et al.7 observed irisin levels up to 60%
lower in 38 non-diabetic patients with CKD than in 19 healthy
controls adjusted for age and gender. The authors indicated
that sarcopenia and indoxyl sulfate-induced inhibition of the
expression of ﬁbronectin type III domain-containing protein
5 (FNDC5) in muscle cells could explain this phenomenon.
A cursory exploratory analysis of selected biochemical val-
ues showed only a slight direct correlation with plasma
n variables.
D Peritoneal dialysis HD
.08) −0.07 (0.71) −0.01 (0.95)
.54) 0.11 (0.57) 0.19 (0.36)
.08) −0.21 (0.21) 0.14 (0.51)
.66) −0.03 (0.90) 0.09 (0.66)
.99) −0.23 (0.26) −0.25 (0.23)
.52) 0.10 (0.64) 0.12 (0.55)
.05) 0.15 (0.35) 0.37 (0.07)
.84) 0.13 (0.52) 0.31 (0.12)
.45) 0.15 (0.46) 0.12 (0.56)
.02) 0.28 (0.16) 0.72 (0.001)
.49) −0.30 (0.13) −0.03 (0.90)
.42) −0.28 (0.19) 0.08 (0.72)
.90) −0.29 (0.14) 0.04 (0.86)
.04) 0.11 (0.60) 0.21 (0.30)
.05) −0.06 (0.78) 0.11 (0.59)
.05) −0.06 (0.77) 0.11 (0.61)
.80) −0.14 (0.49) 0.07 (0.73)
.019) −0.10 (0.70) 0.08 (0.68)
.52) 0.16 (0.43) 0.12 (0.58)
GF1: insulin-like growth factor; BSA: body surface area.
riables, including blood pressure (systolic, diastolic and mean), uric
lobin, calcium, phosphate, PTH and vitamin D, with no signiﬁcant
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Table 5 – Correlations adjusted between serum irisin and main variables.
Variable B 95% CI p
Diabetes mellitus −0.52 −11.69, 10.73 0.93
Body mass index (kg/m2) 1.24 −1.02,  3.50 0.28
Body mass (kg) (BIA) 1.24 −0.80,  3.29 0.23
Lean body mass (kg) (BIA) −0.27 −2.83, 2.30 0.84
GFR (mL/min) 1.89 0.65, 3.13 0.003
Proteinuria (g/24 h) 1.72 −5.70, 9.15 0.64
Cholesterol, plasma (mg/dL) 0.13 −0.10, 0.37 0.29
HDL cholesterol, plasma (mg/dL) 0.66 −0.41, 1.74 0.28
LDL cholesterol, plasma (mg/dL) 0.02 −0.32, 0.36 0.90
Triglycerides, plasma (mg/dL) 0.00 −0.15, 0.16 0.95
Bicarbonate, plasma (mM/L) 3.90 1.79, 6.01 0.001
Interleukin 6, plasma (pg/mL) −0.56 −1.41, 0.30 0.20
C-reactive protein, plasma (mg/dL) −1.14 −5.37, 3.10 0.59
HOMA index 1.03 −1.80, 3.87 0.47
Treatment type
PD vs. ACKD 24.40 1.67, 47.14 0.036
PD vs. haemodialysis 39.39 15.37, 63.40 0.002
Haemodialysis vs. ACKD −6.91 −17.58, 3.76 0.20
BIA: bioimpedance; PD: peritoneal dialysis; ACKD: chronic kidney disease managed conservatively; GFR: glomerular ﬁltration rate; CI: conﬁdence
interval.
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djusted association with age (inverse), HDL cholesterol and
DL cholesterol, and HOMA index (direct). Finally, Liu et al.9
tudied 365 patients with type 2 diabetes and different levels
f GFR, and conﬁrmed the existence of an inverse association
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nverse correlation between age and serum irisin that, remark-
bly, seemed to disappear in patients with lower levels of GFR.
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aemodialysis. **p < 0.001 vs. any other group.tly associated with serum irisin are in bold. The best model includes
other variables (not signiﬁcant) represent the individual correlation
Finally, this analysis did not detect any association with gen-
der, but showed trends, which were not very consistent, in
correlation between irisinaemia and lean body mass and body
fat.
Overall, attempts to characterise irisin secretion patterns
and their correlation with clinical and metabolic markers
have been unsuccessful, and these inconsistencies also affect
patients with CKD. There are several possible explanations for
the discrepancies observed. First, irisin is usually measured
by ELISA, but signiﬁcant variations have been observed in the
estimated values when different kits on the market are used.18
The limitations of knowledge on the synthesis and secretion of
irisin greatly hinder the search to explain these discrepancies,
and has so far prevented normal ranges of serum irisin levels
from being established. Inconsistencies in the estimates also
help to explain the many  contradictions regarding correlations
between irisinaemia, on the one hand, and variables such as,
for example, body fat or lean body mass, insulin resistance and
lipid patterns on the other hand. Moreover, irisin levels have
been investigated in very diverse contexts, which adds confu-
sion to the overall analysis. For example, diabetes or obesity
could signiﬁcantly alter the physiological behaviour of irisin.
Overall, it is clear that more  research is needed to clarify the
signiﬁcance of irisin in health and disease.
Our study conﬁrms previous analyses which indicated a
direct correlation between GFR and irisinaemia. As might
be expected in this context, irisin levels were lower in CKD
patients than in healthy controls (Fig. 1). This difference
affected patients with ACKD as well as those treated with PD or
HD. In addition, patients on PD had higher levels of irisin than
the other 2 groups. To our knowledge, this is the ﬁrst study to
speciﬁcally analyse this issue. The explanation for the differ-
ences is not clear. Patients on HD had a relatively low body fat,
which could contribute to the difference, although this factor
showed no independent association with irisinaemia in our
 0 1 6
r
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study. In the case of ACKD patients, the signiﬁcantly higher
level of GFR allowed this group to maintain raw irisin levels
comparable to those observed in patients on PD. Moreover,
serum bicarbonate levels were higher in PD patients than in
any other group of patients (Table 2), and this variable was
a consistent predictor of irisinaemia. To our knowledge, this
association has not been previously investigated, and we have
no clear explanation for it, although metabolic acidosis has
been mentioned as a determinant behind the secretion of
other adipokines.19
This study has signiﬁcant limitations, including its cross-
sectional, exploratory design, which does not allow for
investigating causality. The statistical power of the sample is
also limited, which might explain some inconsistencies in the
results, although this problem was observed in studies with
larger samples.
In summary, our study conﬁrms that serum levels of irisin
are relatively low in patients with CKD, and there is a direct
association between GFR and levels of this adipomyokine.
In addition, our data indicate that irisinaemia maintains a
consistent and independent relationship with plasma bicar-
bonate levels in patients with CKD. Patients on PD have higher
levels of irisin than patients with ACKD or those treated with
HD. Finally, our data conﬁrm an essential inconsistency in
associations between serum irisin, on the one hand, and
metabolic markers or body composition on the other hand,
as observed in previous studies. Further studies are needed
to characterise the signiﬁcance of abnormal levels of irisin in
CKD.
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